Poldip2 is an oxygen-sensitive protein that controls PDH and αKGDH lipoylation and activation to support metabolic adaptation in hypoxia and cancer

Felipe Paredes, Kely Sheldon, Bernard Lassègue, Holly C. Williams, Elizabeth A. Faidley, Gloria A. Benavides, Gloria Torres, Fernanda Sanhueza-Olivares, Samantha M. Yeligar, Kathy K. Griendling, Victor Darley-Usmar, and Alejandra San Martin

*Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA 30322; †Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294; ‡Division of Pulmonary, Allergy, Critical Care, and Sleep, Department of Medicine, Emory University, Atlanta, GA 30322; and ‡Atlanta Veterans Affairs Medical Center, Decatur, GA 30033

Edited by Hening Lin, Cornell University, Ithaca, NY, and accepted by Editorial Board Member Michael A. Marletta January 5, 2018 (received for review December 3, 2017)

Although the addition of the prosthetic group lipoate is essential to the activity of critical mitochondrial catabolic enzymes, its regulation is unknown. Here, we show that lipoylation of the pyruvate dehydrogenase and α-ketoglutarate dehydrogenase (αKDH) complexes is a dynamically regulated process that is inhibited under hypoxia and in cancer cells to restrain mitochondrial respiration. Mechanistically, we found that the polymerase-δ-interacting protein 2 (Poldip2), a nuclear-encoded mitochondrial protein of unknown function, controls the lipoylation of the pyruvate and α-KDH dihydrolipoamide acetyltransferase subunits by a mechanism that involves regulation of the caseinolytic peptidase (Clp)-protease complex and degradation of the lipoate-activating enzyme Ac-CoA synthetase medium-chain family member 1 (ACSMT). ACSMT is required for the utilization of lipoic acid derived from a salvage pathway, an unacknowledged lipoylation mechanism. In Poldip2-deficient cells, reduced lipoylation represses mitochondrial function and induces the stabilization of hypoxia-inducible factor 1α (HIF-1α) by loss of substrate inhibition of prolyl-4-hydroxylases (PHDs). HIF-1α-mediated retrograde signaling results in a metabolic reprogramming that resembles hypoxic and cancer cell adaptation. Indeed, we observe that Poldip2 expression is down-regulated by hypoxia in a variety of cell types and basally repressed in triple-negative cancer cells, leading to inhibition of lipoylation of the pyruvate and α-KDH complexes and mitochondrial dysfunction. Increasing mitochondrial lipoylation by forced expression of Poldip2 increases respiration and reduces the growth rate of cancer cells. Our work unveils a regulatory mechanism of catabolic enzymes required for metabolic plasticity and highlights the role of Poldip2 as a key during hypoxia and cancer cell metabolism adaptation.

Poldip2 | lipoylation | mitochondria | hypoxia | metabolism

The polymerase-δ-interacting protein 2 (Poldip2; also known as PDIP38 and mitogen 1), a ubiquitously expressed protein (1), was initially identified as a DNA polymerase-δ-interacting protein and a binding partner for the proliferating cell nuclear antigen (2). Later studies showed that homozygous deletion of Poldip2 in mice results in reduced fetal weight and perinatal lethality of unknown cause (3). Adult heterozygous mice have no evident physiological phenotype, but more detailed characterization has shown that they display disrupted extracellular matrix organization with excessive and disorganized collagen deposition (4) and an impaired response to ischemia-induced collateral vessel formation (5). Interestingly, Poldip2 contains an N-terminal mitochondrial localization sequence and has been found to interact with components of the mitochondrial nucleoid (6), suggesting a mitochondrial role that remains unexplored. One of the aims of this study was to understand the function of Poldip2 in the mitochondria.

The α-(R)-lipoic acid (5-[(3R)-1,2-dithiolan-3-yl] pentanoic acid) is a universally conserved fundamental metabolite that serves as a prosthetic group. It is required for the activity of two key catabolic enzymes: the pyruvate dehydrogenase (PDH) and the α-ketoglutarate dehydrogenase (αKGDH) complexes. Specifically, α-lipoic acid is covalently attached to dihydrolipoamide S-acetyltransferase (DLAT) and dihydrolipoamide S-cysteinytransferase (DLST), the dihydrolipoyl transacylase (or E2) subunits of the PDH and the αKGDH, respectively.

Lipoic acid synthesis and the mechanisms leading to protein lipoylation have been investigated most thoroughly in *Escherichia coli* and, recently, in *Saccharomyces cerevisiae*, but they are still poorly understood in mammals. Currently, two mammalian pathways are proposed. In the first, which is evolutionarily conserved, lipoic acid is synthesized in the mitochondria from an octanoyl-acyl carrier protein provided by the fatty acid synthesis pathway. The octanoyl moiety is attached to lipoate-dependent enzymes by the ligase LIPT2. Next, the [Fe–S] cluster-containing enzyme LIAS catalyzes the radical-mediated insertion of two sulfur atoms into the C-6 and C-8 positions of the octanoyl moiety bound to the lipoyl domains of lipoate-dependent enzymes. The second and less characterized is the salvage pathway, which uses exogenous lipoate that is taken up via the sodium-dependent multivitamin transporter (7, 8). Exogenously scavenged lipoic acid is then activated by addition of AMP and transferred to lipoate-containing enzymes. In contrast to bacteria and yeast,
where one enzyme executes both reactions, mammals require two separate enzymes for the activation and ligation reaction of lipoylate (9). Indeed, the isolation of a unique lipoic acid-activating enzyme (lipoic acid + ATP → lipoyl-NMP) from bovine heart mitochondria (9). Additionally, our work on the contribution of ACSM1 to lipoylation remains unexplored.

The caseinolytic peptidase (Cp) complex is a mitochondrial matrix protease from the ATPase associated with the diverse cellular activity (AAA+) superfamily (12). The Cp complex is a proteasome-like cylinder composed of the CLP proteolytic subunit (CLPP) and the ATP/chaperone component ClpX-like (CLPX), which is thought to be responsible for targeting specific substrates for degradation (13). CLPP and CLPX are evolutionarily conserved from bacteria to humans. Recently, the activity of the Clp-protease complex has been implicated in cellular metabolism (14), although its mechanism of regulation is unknown.

Here, we show that Poldip2 governs a critical mechanism linking Clp, ACSM1, and protein lipolysis, thus regulating mitochondrial function. Reduced Poldip2 expression triggers the Clp-protease complex-mediated degradation of ACSM1, which prevents PDH and αKGDH complex lipolysis, inhibiting their activity, and represses mitochondrial function. The inhibition of the tricarboxylic acid (TCA) cycle and oxidative respiration reduces the amount of α-ketoglutarate (α-KG), with resultant metabolic inhibition of prolyl-hydroxylases and hypoxia-inducible factor 1α (HIF-1α)–mediated retrograde signaling. We show that the addition of the prosthetic group, lipoic acid, to catabolic enzymes is a regulated process controlled through a particular mammalian salvage pathway of lipolysis. Additionally, our work reveals that Poldip2 is a regulator of cell metabolism and mitochondrial function that participates in metabolic adaptation.

Results

Poldip2 contains an N-terminal mitochondrial localization sequence that predicts it will be localized to the mitochondrion (15). Indeed, to begin to define its function, we investigated the subcellular distribution of Poldip2. As predicted from the primary sequence, we found that endogenous Poldip2 localizes almost exclusively to the mitochondria in a variety of cell types, including human aortic smooth muscle cells (HASMCs) (Fig. 1A), human mammary epithelial cells (HMECs), and mouse embryonic fibroblasts (MEFs) (Fig. S1). Poldip2 was detected at an apparent molecular mass of 37 kDa, which corresponds to the predicted molecular mass of the mitochondrial protease-processed form (16, 17).

The role of Poldip2 in the mitochondria is unknown. Therefore, to investigate its distinct contribution to mitochondrial function, we performed a series of experiments manipulating Poldip2 expression. Using extracellular flux analysis to determine cellular bioenergetics as a function of time (Fig. 1B), we found that Poldip2-deficient cells display a lower ratio of basal oxygen consumption rate to extracellular acidification rate (OCR/ECAR), lower OCR/ECAR associated with ATP synthesis, and lower OCR/ECAR maximal capacity (Fig. 1C). Despite the fact that Poldip2 deficiency represses mitochondrial function, we did not observe a reduction in mitochondrial biogenesis (102 ± 14%, P = 0.9 at 24 h; 94 ± 7%, P = 0.5 at 72 h), and even though Poldip2-deficient cells produce less ATP by oxidative respiration, total cellular ATP levels were preserved (4.4 ± 0.8 vs. 4.8 ± 0.6 cd/μg of protein, P = 0.7). These data suggest a potential cellular reprogramming with up-regulation of glycolysis that was confirmed by an increased ECAR compared with OCR, as shown in the energy map (Fig. 1D). In fact, we found that Poldip2 down-regulation stabilizes HIF-1α and induces expression of PDH kinase (PDK) and, consequently, the inhibitory phosphorylation of the PDH E1α subunit of the PDH complex in HASMCs (Fig. 2A). Similar results were found in MEFs from Poldip2−/− mice as well as with two unrelated siRNAs against Poldip2 (Fig. S2). As expected, the induction of PDK and phospho-PDH induced by Poldip2 deficiency was reversed by down-regulation of HIF-1α (Fig. S3). Normally, HIF-1α has a
Forced expression of ACSM1 reverses the phenotype of Poldip2-deficient cells. (A) Left) Western blot showing the effect of ACSM1 forced expression in siControl- and siPoldip2-treated cells on the lipoylation of DLAT and DLST. (A, Right) Box plots represent mean ± SE from six independent experiments. (B and C) PDH and αKGDH activities in isolated mitochondria from Poldip2-deficient cells. All data are presented as mean ± SE from three to six independent experiments.

half-life of minutes, as it is constantly hydroxylated by a member of the prolyl-4-hydroxylase (PHD) family, and is then recognized by an E3 ubiquitin ligase complex, polyubiquitinated, and degraded by the proteasome (18, 19). PHDs use molecular oxygen and α-KG as cosubstrates for their catalytic reaction. It is known that under oxygen concentrations below their Kₘ of about 250 μM, PHD activity is inhibited and HIF-1α is stabilized (20). Similarly, PHD activity is dependent on the availability of α-KG even in the presence of oxygen. For example, disruption or deregulation of TCA cycle enzymes inhibits PHDs, with subsequent metabolic-mediated stabilization of HIF-1α (21). Since Poldip2 down-regulation stabilizes HIF-1α under normoxia, we hypothesized that this was a consequence of metabolic inhibition of PHD2. In support of this idea, we found that Poldip2-deficient cells have significantly lower concentrations of α-KG (Fig. 2B) and that HIF-1α stabilization was reversed when the cell-permeable α-KG derivative α-KG octyl ester (1 mM) was added to the culture media (Fig. 2C). Because α-KG is a key intermediate metabolite in the TCA cycle, we investigated whether Poldip2 regulates the activity of the TCA cycle enzymes. Gene expression data in Caenorhabditis elegans predicts a functional association between the products of tag-307 and gip-2 (22). Interestingly, the putative homologs of tag-307 and gip-2 in humans are the genes Poldip2 and lipoxygenase 1 (LIPT1), respectively. LIPT1 is a nuclear-encoded mitochondrial protein proposed to participate in a functional mammalian salvage pathway of lipoylation, that is, to catalyze the transfer of the lipoyl group from lipoyl-AMP to the specific lysine residue of lipoyl domains of lipoate-dependent enzymes, two of which participate in oxidative catalysis: the PDH and αKGDH complexes. The lipoylation occurs in the E2 subunit DLAT of PDH and DLST of αKGDH. Therefore, we evaluated if LIPT1 expression and protein lipoylation were affected in Poldip2-deficient cells. We found that lack of Poldip2 significantly reduces lipoyl-DLAT and lipoyl-DLST in HASMCs (Fig. 3A). Similar results were obtained with two unrelated siRNA sequences against Poldip2 and in Poldip2−/−MEFs, Fig. S4 A–C). Consistent with the reduction in the addition of the prosthetic group lipoate, the activities of PDH and αKGDH were significantly inhibited in Poldip2-deficient cells (Fig. 3 B and C). Interestingly, despite defective lipoylation, LIPT1 expression was increased (Fig. 3A), suggesting an ineffective compensatory mechanism presumably induced by a shortage in the substrate for the LIPT1-catalyzed reaction. Consistent with the notion that Poldip2 down-regulation produces a deficit in LIPT1 substrate, we observed an almost complete loss of ACSM1, the proposed lipoic acid-activating enzyme, in Poldip2-deficient HASMCs (Fig. 3A). Similar results were obtained with two unrelated siRNA sequences against Poldip2 and in Poldip2−/−MEFs, Fig. S4 A–C). Interestingly, 11.5 d post coitum (dpc) Poldip2−/−embryos exhibit a similar reduction of ACSM1 levels (Fig. S4D). Indeed, ACSM1 down-regulation produces a similar reduction in DLAT and DLST lipoylation (Fig. S5). More importantly, forced expression of ACSM1 in Poldip2-deficient cells was sufficient to rescue lipoylation levels (Fig. 4A) and to reverse metabolic shift (Fig. 4B). These data indicate that loss of ACSM1 is the primary mechanism by which Poldip2 deficiency inhibits lipoylation. To understand the mechanism by which Poldip2 controls ACSM1 levels, we examined its potential binding partners within the mitochondria. Immunoprecipitated protein complexes containing myc-tagged Poldip2 were subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS). The ATP-dependent Clp-protease ATP-binding subunit CLPX was the top-ranked molecule associated with Poldip2 (Fig. 5A). This interaction was...
confirmed by coimmunoprecipitation of CLPX with the overexpressed and endogenous Poldip2 protein (Fig. 5B). As noted, CLPX is a chaperone ATPase that binds to the caseinolytic peptidase CLPP to form the Clp-protease complex. CLPX acts as an energy-dependent unfoldase required to allow the entrance of proteins to the CLPP-composed barrel-shaped chamber that, otherwise, is too small for the access of native proteins (23). CLPX is also thought to be responsible for substrate specificity of the Clp-protease complex (13).

The specific binding between Poldip2 and CLPX suggests to us that Poldip2 may inhibit Clp-protease complex activity by sequestering CLPX and that the Poldip2 deficiency is sufficient to activate the Clp-protease complex and degrade ACSM1. In fact, in CLPP-deficient cells, Poldip2 down-regulation fails to induce the degradation of ACSM1. Consequently, the DLAT and DLST lipoylation is preserved (Fig. 5C). PHD2 is not inhibited, and the HIF-1α stabilization is absent (Fig. 5C). These data demonstrate that Poldip2 governs a mitochondrial pathway responsible for the Clp-protease complex–mediated degradation of ACSM1, which impairs lipoylation of the PDH and αKGDH complexes, limits mitochondrial respiration, and induces HIF-1α retrograde signaling (Fig. 6).

The cellular changes induced by Poldip2 deficiency are similar to those observed during cellular adaptation to hypoxic conditions. Therefore, we evaluated if oxygen tension regulates its expression. Indeed, Poldip2 expression is dramatically repressed under hypoxic conditions in HASMCs (Fig. 7A), human cardiac ventricular fibroblasts (HVF), HMECs, and MEFs (Fig. S6). Since oxygen tension regulates Poldip2, we evaluated the relevance of this mechanism under hypoxia. As shown in Fig. 7B, hypoxia significantly reduces ACSM1 protein amount and the level of DLST and DLAT lipoylation at the same time that it induces stabilization of HIF-1α. Exogenous Poldip2 expression under hypoxia was sufficient to restore the levels of ACSM1, lipoyl-DLST, and lipoyl-DLAT.

Hypoxia-induced metabolic adaptation is directly connected to oncogenic signaling. Indeed, impaired mitochondrial functions and increased glycolysis offer cancer cells an advantage to better produce biomass to proliferate, survive, and become invasive in the tumor microenvironment. In particular, subtypes of breast cancers lacking the estrogen receptor, the progesterone receptors, and the epidermal growth factor receptor-2 [triple-negative breast cancer (TNBC)] are highly glycolytic (in vitro OCR/ECAR = 2–5 pmol/mP) and have an unfavorable clinical prognosis compared with estrogen receptor ER+ (in vitro OCR/ECAR = 15–20 pmol/mP) (24). We hypothesized that Poldip2 deficiency may contribute to the highly glycolytic phenotype of TNBC. To test this idea, we compared three lines of breast cancer cells: the highly oxidative T47D and the TNBC highly and glycolytic lines MDA-MB-231 and BT549. Fig. S4 shows that, consistent with our hypothesis, TNBCs have significantly lower Poldip2 expression and completely inhibited DLAT and DLST lipoylation, suggesting that the inhibition of Poldip2 expression may contribute to the metabolic shift observed in this cell line. To further test the role of Poldip2 in the mitochondrial dysfunction observed in TNBC, we expressed Poldip2 in BT549 cells and evaluated the impact on mitochondrial function and protein lipoylation. As shown in Fig. S8A, overexpression of Poldip2 was sufficient to stabilize ACSM1, dramatically increase the lipoylation of the PDH and αKGDH complexes, and reduce the stabilization of HIF-1α under normoxia. Consistent with these biochemical changes,
mitochondrial respiration was significantly increased by Poldip2 expression (Fig. 8C). Importantly, increased lipoylation and mitochondrial function was accompanied by a significant inhibition of cell growth (Fig. 8D).

**Discussion**

Regulation of mitochondrial respiration is essential for the metabolic plasticity needed to adapt to different physiological conditions. Herein, we demonstrate that the regulation of the lipoylation of two key enzymes of the TCA cycle contributes to this plasticity. We found that this mechanism involves nuclear control of Poldip2 expression, which regulates the degradation of the lipoic acid-activating enzyme ACSM1.

The activation of lipoic acid and its subsequent transfer to lipoate-containing enzymes was initially postulated by Reed (25). Later studies confirmed that such activity was present in bovine liver (10), and, more recently, it was identified as the product of the ACSM1 gene (11). However, the contribution of ACSM1 to mitochondrial peptidases are regulated by oxygen and participate in an integrated hypoxic response needed for metabolic adaptation.

It is well established that HIF-1α depresses mitochondrial respiration by inhibiting the oxidation of pyruvate by the mitochondria due to transcriptional up-regulation of PDH kinase and subsequent increase in the inhibitory phosphorylation of PDH. Poldip2 deficiency negatively impacts PDH activity by increasing PDK-mediated phosphorylation and inhibiting LIPT1-mediated lipoylation. However, additional studies are required to define the relative contributions of these posttranslational modifications on PDH activity.

We found that Poldip2 expression is down-regulated in hypoxia and cancer cells. During these conditions, loss of Poldip2 may lead to ACSM1 and lack of LIPT1-mediated lipoylation only affects the lipoylation of PDH and αKGDH. This is in agreement with the fact that, in contrast to mutations in genes from the lipoic acid biosynthesis pathway that affect all lipoate-dependent enzymes (26–28), two cases of LIPT1 mutations in humans showed low lipoylation of the PDH and αKGDH complexes but no alteration in glycine metabolism or accumulation of branched-chain amino acids in the urine (29, 30). This suggests that the ACSM1/LIPT1-mediated lipoylation pathway may preferentially target substrates from oxidative catabolism.

Homozygous deletion of Poldip2 results in fetal growth inhibition and perinatal lethality (3) of unknown cause. The dramatic reduction of ACSM1 in Poldip2−/− embryos suggests that lactic acidosis may account for the subsequent perinatal lethality (31), as has been observed in a human case of lipoamide dehydrogenase deficiency (32), in which the reduced dihydrolipoamide is not oxidized to restore the electrophile lipoamide, and therefore cannot be used for catalysis.

The mechanism of Poldip2-mediated ACSM1 degradation involves Clp-protease complex activation. Of mostly unknown function in humans, CLPP and CLPX have been extensively studied in prokaryotes, where they act mostly as a quality control mechanism. Importantly, our work also reveals that mitochondrial peptidases are regulated by oxygen and participate in an integrated hypoxic response needed for metabolic adaptation.

**Fig. 7**. Poldip2 is an oxygen-sensitive protein that controls protein lipoylation under hypoxia. (A, Left) Poldip2 in HASMCs cultured under normoxia or hypoxia for 48 h. (A, Right) Box plots represent the mean ± SE from four to six independent experiments. (B, Left) Western blot of ACSM1 expression and protein lipoylation in cells infected with control adenovirus or AdPoldip2 after being maintained under normoxia or hypoxia for 48 h. (B, Right) Box plots represent the mean ± SE from four to six independent experiments. Symbols above boxes indicate statistical significance. Pairs of bars that do not share any symbol are significantly different from each other.
**Materials and Methods**

**Animals.** Poldip2 gene trap mice on a C57BL/6 background were produced by the Texas A&M Institute for Genomic Medicine. A gene trap construct was inserted into the first intron of Poldip2 in mouse embryonic stem cells. Characterization of these mice has been published previously (4). Embryos between 11.5 and 12.5 dpc were isolated as described below, fixed in paraformaldehyde, and sliced for immunohistochemistry.

**Cell Culture and Transfection.** HASMCs and HMECs were obtained from Thermo Fisher Scientific. HVFs were obtained from Lonza. Human epithelial cells from invasive ductal carcinoma (T47D and BT549) and adenocarcinoma (MDA-MB231) were obtained from the American Type Culture Collection. Cells were grown as recommended by the vendor in base media with the addition of growth supplements. After cells reached ~80% confluence, growth supplements were removed 24 h prior to experiments. MEFs were prepared from embryonic day 13.5 embryos as previously described (3). Hoxip experiments were performed using a HypoxStatin H3S. Cells were transfected using Lipofectamine RNAiMAX.

**Cell Fractionation.** Cells were washed with PBS, and scraped in 1x buffer A provided by the cell fractionation kit (ab109719; Abbam) according to the manufacturer's protocol. For mitochondrial biogenesis, we used the Human Mitochondrial DNA Monitoring Primer Set (catalog no. 7246; Clontech/Takara) in nuclear and mitochondrial DNA extracted with a PureLink Genomic DNA Kit (catalog no. K1820-01; Invitrogen) as recommended by the manufacturers.

1. Lyons AN, et al. (2009) Poldip2, a novel regulator of Nox4 and cytoskeletal integrity in vascular smooth muscle cells. *Circ Res* 105:249–259.
2. Liu L, Rodriguez-Belmonte EM, Mazloum N, Xie B, Lee MY (2003) Identification of a polymerase δ interacting protein 2 knockout mouse. *J Biol Chem* 278:10041–10047.
3. Brown DJ, et al. (2014) Poldip2 knockdown results in perinatal lethality, reduced cellular growth and increased apoptosis of mouse embryonic fibroblasts. *PLoS One* 9:e96657.
4. Sutliff RL, et al. (2013) Polymerase delta interacting protein 2 sustains vascular structure and function. *Arterioscler Thromb Vasc Biol* 33:2154–2161.
5. Amaro AM, et al. (2014) Polymerase δ-interacting protein 2 promotes posttranslational neovascularization of the mouse hindlimb. *Arterioscler Thromb Vasc Biol* 34:1548–1555.
6. Cheng X, et al. (2005) PDIP38 associates with proteins constituting the mitochondrial DNA nucleoid. *J Biol Chem* 183:673–678.
7. Prasad RD, et al. (1998) Cloning and functional expression of a cDNA encoding a mammalian sodium-dependent vitamin transporter mediating the uptake of pantethine, biotin, and lipoate. *J Biol Chem* 273:7501–7506.
8. Wang H, et al. (1999) Human placental Na+-dependent multivitamin transporter. Cloning, functional expression, gene structure, and chromosomal localization. *J Biol Chem* 274:14875–14883.
9. Morris TW, Reed KE, Cronan JE, Jr (1995) Lipid acid metabolism in Escherichia coli: The iplA and lipB genes define redundant pathways for ligation of lipoyl groups to apoproteins. *J Bacteriol* 177:1–10.
10. Tsunoda JN, Yasunobu KT (1967) Mammalian lipoic acid activating enzyme. *Arch Biochem Biophys* 118:395–401.
11. Fujiwara K, Takeuchi S, Okamura-Ikeda K, Motokawa Y (2001) Purification, characterization, and cDNA cloning of lipoate-activating enzyme from bovine liver. *J Biol Chem* 276:28819–28823.
12. Garda CA, Schimmer AD (2014) Mitochondrial matrix proteases as novel therapeutic targets in malignancy. *Oncogene* 33:2690–2699.
13. Kang SG, et al. (2002) Functional proteolytic complexes of the human mitochondrial ATP-dependent protease, hClpXP. *J Biol Chem* 277:21095–21102.
14. Fisher D, Langer JD, Osiewacz HD (2015) Identification of potential mitochondrial CLPKP protease interactors and substrates suggests its central role in energy metabolism. *Sci Rep* 5:18375.
15. Emanuelsson O, Nielsen H, Brunak S, von Heijne G (2007) Predicting subcellular localization of proteins based on their N-terminal amino acid sequence. *J Mol Biol* 300:1005–1016.
16. Indio V, Martelli PL, Fariselli P, Casadio R (2013) The prediction of organelle targeting peptides in eukaryotic proteins with Grammatical Restrained Hidden Conditional Random Fields. *Bioinformatics* 29:981–988.
17. Savajorda C, Martelli PL, Farielli P, Casadio R (2014) TPhred2: Improving the prediction of mitochondrial targeting peptide cleavage sites by exploiting sequence motifs. *Bioinformatics* 30:2973–2974.
18. Huang LE, Gu J, Schau M, Bunn HF (1998) Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteosome system. *Oncogene* 17(29):4039–4047.
19. Saldana S, Caro J (1997) Hypoxia-inducible factor 1α (HIF-1α/α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. *J Biol Chem* 272:22662–22667.
20. Semenza GL, Wang GL (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol Cell Biol* 12:5447–5454.
21. Mackenzie ED, et al. (2007) Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate-dehydrogenase-deficient cells. *Mol Cell Biol* 27:3282–3289.
22. Sklarz DC, et al. (2011) The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res* 39:D561–D568.
23. Baker TA, Sauer RT (2012) ClpP, an ATP-powered unfolding and protein-degradation machine. *Biochim Biophys Acta* 1823:15–28.
24. Pelicano H, et al. (2014) Mitochondrial dysfunction in some triple-negative breast cancer cell lines: Role of mTOR pathway and therapeutic potential. *Breast Cancer Res* 16:434.
25. Reed LJ (1957) The chemistry and function of lipidic acid. *Ady Enzymol Relat Subj Biochem* 18:318–347.
26. Tsurusaki Y, et al. (2015) Novel compound heterozygous LIAS mutations cause glentine encephalopathy. *J Hum Genet* 60:631–635.
27. Baker PR, 2nd, et al. (2014) Variant non ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX5. *Brain* 137:366–379.
28. May J, et al. (2011) Lipoic acid synthesis deficiency causes neonatal-onset epilepsy, defective mitochondrial energy metabolism, and glucose elevation. *Am J Hum Genet* 89:792–797.
29. Soreze Y, et al. (2013) Mutations in human lipoate/acyltransferase gene LIP1 cause a Leigh disease with secondary deficiency for pyruvate and alpha-ketoglutarate dehydrogenase. *Orphanet J Rare Dis* 8:192.
30. Tort F, et al. (2014) Mutations in the lipoate/acyltransferase LIP1 gene cause a fatal disease associated with a specific lipidolysis defect of the 2-ketoacid dehydrogenase complex. *Hum Mol Genet* 23:1907–1915.
31. Lo YF, et al. (2011) Severe metabolic acidosis causes early lethality in NBC1 W516X knock-in mice as a model of human isolated proximal renal tubular acidosis. *Kidney Int* 79:730–741.
32. Matalon R, et al. (1984) Lipoamide dehydrogenase deficiency with primary lactic acidosis: Favorable response to treatment with oral lipoic acid. *J Pediatr* 104:60–69.
33. Dranka BP, et al. (2011) Assessing bioenergetic function in response to oxidative stress by metabolic profiling. *Free Radic Biol Med* 51:1621–1635.